Focused On-demand Library for Cytochrome b5 reductase 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q7L1T6

UPID:

NB5R4_HUMAN

Alternative names:

Flavohemoprotein b5/b5R; N-terminal cytochrome b5 and cytochrome b5 oxidoreductase domain-containing protein; cb5/cb5R

Alternative UPACC:

Q7L1T6; B1AEM2; Q5TGI9; Q9NUE4; Q9UHI9

Background:

Cytochrome b5 reductase 4, also known as Flavohemoprotein b5/b5R, plays a pivotal role in the endoplasmic reticulum stress response pathway. It is instrumental in safeguarding pancreatic beta-cells from oxidative stress by mitigating the accumulation of reactive oxygen species (ROS). This enzyme exhibits versatility in reducing various substrates, including cytochrome c, ferricyanide, and methemoglobin.

Therapeutic significance:

Understanding the role of Cytochrome b5 reductase 4 could open doors to potential therapeutic strategies. Its critical function in protecting cells from oxidative damage highlights its potential as a target for developing treatments aimed at enhancing cellular resilience to stress.